BrainFocus Labs S.L.

BrainFocus operates at the intersection of neurotechnology, medical software, epilepsy diagnostics, and medical devices. Its target use case is specialized: helping clinical teams interpret intracranial EEG in patients with drug-resistant epilepsy and identify seizure-related brain regions. The company’s differentiation is based less on a broad digital-health platform than on workflow depth for epilepsy surgery evaluation. BrainFocus iEEG is described as combining video-EEG, quantitative metrics, MRI, CT, PET, electrode trajectories, and anatomical segmentation, while generating transparent maps that complement clinicians’ visual review. The Low Entropy Map method provides a proprietary technical angle focused on spatially localized brain activity and seizure-focus prediction. BrainFocus’s small, Barcelona-based operating footprint and classification as a medical-device and health-diagnostics company suggest an early specialist position rather than an established scaled vendor. Its market opportunity depends on clinical validation, regulatory progress, integration into hospital epilepsy workflows, and evidence that quantitative maps improve diagnostic efficiency or surgical planning.

BrainFocus’s trajectory appears to be research-led and early stage. The company was founded in 2023, while the recorded start of co-founder and strategic advisor Bart Huisken’s role in May 2020 suggests that the underlying initiative or advisory relationship predates the current legal operating profile. The business is built around BrainFocus iEEG, a focused diagnostic product rather than a portfolio of disclosed offerings. Its development path combines computational neuroscience, signal processing, and multimodal neuroimaging, with the Low Entropy Map method serving as a central intellectual-property asset. Current staffing is represented by one featured position and an employee band of one to ten, indicating a very small team. Consequently, the clearest inflection point is the transition from long-running academic and clinical research into a dedicated company founded in 2023. Further trajectory assessment requires evidence of validation studies, regulatory submissions, hospital deployments, commercial adoption, or team expansion.